Zealand Pharma A/S (ZEAL.CO) — Quality & forensics

As of 2026-09-01 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.

The Closelook module scores

60 /100 composite · 7 modules · general weight set

Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.

Financial forensics — the academic screens

10.57 Altman Z-Score

Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.

8/9 Piotroski F-Score

Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.

126.98 Beneish M-Score

Screens reported earnings for statistical manipulation patterns — above the −1.78 threshold the literature flags for earnings-manipulation risk. A screen, not an accusation.

FAQ · from the current data · as of 2026-09-01

Quick answers

What is Zealand Pharma A/S's Closelook quality reading?

The composite reads 60/100 across 7 modules, as of 2026-09-01: valuation 80, quality 70, growth 37, balance sheet 86, cash quality 59, capital allocation 53, momentum 21. Closelook scores are research diary readings, not ratings or investment advice.

What is Zealand Pharma A/S's Altman Z-Score?

10.57, which sits in the safe zone (above 2.99) as of 2026-09-01. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.

What is Zealand Pharma A/S's Piotroski F-Score?

8 of 9, as of 2026-09-01. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.

What does Zealand Pharma A/S's Beneish M-Score indicate?

126.98 — above the −1.78 threshold the literature flags for earnings-manipulation risk, as of 2026-09-01. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.

Related in the Closelook universe